Market Overview:
The global soft mist inhalers (SMI) market is expected to register a CAGR of 6.5% during the forecast period, 2018-2030. The SMI market is segmented on the basis of type, application and region. On the basis of type, the SMI market is segmented into asthma and COPD. Asthma held a dominant share in 2017 and is expected to maintain its dominance during the forecast period as well. COPD held a minor share in 2017 but is projected to grow at a higher CAGR than asthma during the forecast period owing to increasing prevalence of COPD across globe Soft Mist Inhalers are used for delivering medications directly into lungs for treatment purposes such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis etc., which results in better patient compliance & improved therapeutic outcomes over traditional delivery devices such as metered dose inhalers (MDIs).
Product Definition:
A soft mist inhaler (SMI) is a device that delivers medication to the lungs as a mist. The medication is aerosolized, meaning it is turned into a fine spray. This makes it easier for the medication to reach the small airways in the lungs. Soft mist inhalers are often used to treat asthma and other respiratory conditions.
Asthma:
Asthma is a respiratory disease of the lungs characterized by wheezing, chest tightness or pain and frequent shortness of breath. According to the WHO, asthma affects around 334 million people worldwide with more than 90% of cases occurring in developing countries. The number of new cases reported each year is estimated to be around 3 million which includes both severe and mild forms.
COPD:
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory disease that causes airflow obstruction due to the enlargement of mucous membranes and muscle fibers in the lungs. The major symptoms include cough, shortness of breath, wheezing, and chest tightness.
The global SMI market was valued at USD 2.6 billion in 2016.
Application Insights:
The clinic application segment led the global soft mist inhalers (SMI) market in 2017. Clinic-based testing, diagnosis and treatment of respiratory diseases are some of the major factors driving the demand for SMI. In addition, an increasing number of clinics offering diagnostic services for respiratory diseases is expected to further propel industry growth over the forecast period.
Hospital application segment is anticipated to witness a significant CAGR during the forecast period owing to rising awareness about effective treatment methods and availability of advanced healthcare facilities across various regions globally. Furthermore, an increase in hospital admissions due to respiratory illnesses is likely to drive demand for SMI over the forecast period. However, adverse effects caused by improper usage or design flaws in these devices may limit their adoption rate among hospitals worldwide; this factor may hinder market growth during future years.
The others application segment includes care homes.
Regional Analysis:
North America dominated the global market in 2017 owing to high awareness levels regarding SMI, availability of highly advanced devices and well-established healthcare infrastructure. Moreover, increasing prevalence of respiratory disorders is also expected to drive the demand for SMI in this region. For instance, according to data published by CDC’s National Center for Health Statistics (NCHS), between 2010 and 2014 around 18% population aged 6+ years suffered from asthma. Rising adoption of new technologies coupled with favorable reimbursement policies are further fueling growth in this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to rising disposable income leading towards improvement in quality of life along with growing target population base especially those suffering from chronic respiratory diseases such as COPD or asthma that require long term treatment using an inhaler device at home or clinic settings thereby reducing cost burden on patients as compared to hospitalization settings.
Growth Factors:
- Increasing prevalence of respiratory diseases: The global prevalence of respiratory diseases is increasing due to the changing lifestyle and environmental conditions. This is expected to drive the demand for soft mist inhalers in the coming years.
- Growing awareness about asthma and other respiratory disorders: There is a growing awareness among people about asthma and other respiratory disorders, which is likely to boost the demand for soft mist inhalers in the near future.
- Technological advancements: The technological advancements in SMI devices are helping to improve their performance, which is likely to fuel their growth in the coming years.
- Rising number of product launches: The number of product launches by various players in this market is rising, owing to the increasing demand for SMI devices worldwide. This will further boost the growth of this market during forecast period 2017-2025 . 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Soft Mist Inhalers (SMI) Market Research Report
By Type
Asthma, COPD
By Application
Clinic, Hospital, Others
By Companies
3M, Hovione, Mannkind, Meda, Novartis, 3M
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
197
Number of Tables & Figures
138
Customization Available
Yes, the report can be customized as per your need.
Global Soft Mist Inhalers (SMI) Market Report Segments:
The global Soft Mist Inhalers (SMI) market is segmented on the basis of:
Types
Asthma, COPD
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- 3M
- Hovione
- Mannkind
- Meda
- Novartis
- 3M
Highlights of The Soft Mist Inhalers (SMI) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Asthma
- COPD
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Soft Mist Inhalers (SMI) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A soft mist inhaler (SMI) is a type of nebulizer that uses a compressor to create a fine spray of medication. The medication is delivered through the mouth into the lungs, where it can be absorbed by the lungs and transported to other parts of the body. SMI's are often used to deliver medications for asthma, COPD, and other respiratory conditions.
Some of the major players in the soft mist inhalers (smi) market are 3M, Hovione, Mannkind, Meda, Novartis, 3M.
The soft mist inhalers (smi) market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Soft Mist Inhalers (SMI) Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Soft Mist Inhalers (SMI) Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Soft Mist Inhalers (SMI) Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Soft Mist Inhalers (SMI) Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Soft Mist Inhalers (SMI) Market Size & Forecast, 2018-2028 4.5.1 Soft Mist Inhalers (SMI) Market Size and Y-o-Y Growth 4.5.2 Soft Mist Inhalers (SMI) Market Absolute $ Opportunity
Chapter 5 Global Soft Mist Inhalers (SMI) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Soft Mist Inhalers (SMI) Market Size Forecast by Type
5.2.1 Asthma
5.2.2 COPD
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Soft Mist Inhalers (SMI) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Soft Mist Inhalers (SMI) Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Soft Mist Inhalers (SMI) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Soft Mist Inhalers (SMI) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Soft Mist Inhalers (SMI) Analysis and Forecast
9.1 Introduction
9.2 North America Soft Mist Inhalers (SMI) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Soft Mist Inhalers (SMI) Market Size Forecast by Type
9.6.1 Asthma
9.6.2 COPD
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Soft Mist Inhalers (SMI) Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Soft Mist Inhalers (SMI) Analysis and Forecast
10.1 Introduction
10.2 Europe Soft Mist Inhalers (SMI) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Soft Mist Inhalers (SMI) Market Size Forecast by Type
10.6.1 Asthma
10.6.2 COPD
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Soft Mist Inhalers (SMI) Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Soft Mist Inhalers (SMI) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Soft Mist Inhalers (SMI) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Soft Mist Inhalers (SMI) Market Size Forecast by Type
11.6.1 Asthma
11.6.2 COPD
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Soft Mist Inhalers (SMI) Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Soft Mist Inhalers (SMI) Analysis and Forecast
12.1 Introduction
12.2 Latin America Soft Mist Inhalers (SMI) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Soft Mist Inhalers (SMI) Market Size Forecast by Type
12.6.1 Asthma
12.6.2 COPD
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Soft Mist Inhalers (SMI) Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Soft Mist Inhalers (SMI) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Soft Mist Inhalers (SMI) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Soft Mist Inhalers (SMI) Market Size Forecast by Type
13.6.1 Asthma
13.6.2 COPD
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Soft Mist Inhalers (SMI) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Soft Mist Inhalers (SMI) Market: Competitive Dashboard
14.2 Global Soft Mist Inhalers (SMI) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 3M
14.3.2 Hovione
14.3.3 Mannkind
14.3.4 Meda
14.3.5 Novartis
14.3.6 3M